Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2021 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
August 16, 2021 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Top-line data from ongoing Phase 1 proof of concept clinical trial of TERN-501 expected in 4Q 2021Top-line data readout from Part 1 of ongoing AVIATION Trial of TERN-201 expected in 1H 2022Cash and...
August 03, 2021 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
June 24, 2021 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH Sustained VAP-1 inhibition with TERN-201 may make it suitable for...
June 14, 2021 07:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus, and both a differentiated pruritus and lipid profile in patients with NASH First 12-week controlled trial...
June 13, 2021 17:00 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
May 19, 2021 17:00 ET | Source: Terns Pharmaceuticals, Inc.

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

FOSTER CITY, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
May 13, 2021 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update

FOSTER CITY, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
April 07, 2021 07:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns to Present at the 19th Annual Virtual Needham HealthCare Conference

FOSTER CITY, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
March 30, 2021 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

-Terns ended 4Q 2020 with $75 million in cash and cash equivalents and completed an upsized initial public offering in February 2021, raising approximately $147 million in gross proceeds to support...